The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 29, 2023

Filed:

Apr. 17, 2018
Applicant:

Tempest Therapeutics, Inc., Brisbane, CA (US);

Inventors:

Yalda Bravo, San Diego, CA (US);

Jason David Burch, Pointe-Claire, CA;

Austin Chih-Yu Chen, San Marcos, CA (US);

Joe Fred Nagamizo, San Diego, CA (US);

Assignee:

TEMPEST THERAPEUTICS, INC., Brisbane, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/437 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/416 (2006.01); A61K 31/4184 (2006.01); A61K 39/395 (2006.01); C07D 209/08 (2006.01); C07D 231/56 (2006.01); C07D 235/06 (2006.01); C07D 403/12 (2006.01); C07D 413/10 (2006.01); C07D 471/04 (2006.01); A61P 35/00 (2006.01); C07D 209/18 (2006.01); C07D 235/08 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/437 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/416 (2013.01); A61K 31/4184 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07D 209/08 (2013.01); C07D 209/18 (2013.01); C07D 231/56 (2013.01); C07D 235/06 (2013.01); C07D 235/08 (2013.01); C07D 403/12 (2013.01); C07D 413/10 (2013.01); C07D 471/04 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01);
Abstract

The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.


Find Patent Forward Citations

Loading…